10x Genomics (TXG) Q2 2026 Earnings Call Transcript

10x Genomics reported Q2 revenue of $151.0M (+3% YoY excluding $1.6M in non-recurring settlement revenue) and raised FY2026 guidance to $610M–$630M. Gross margin expanded to 74% from 72% (helped by $2.6M tariff refunds), while operating loss narrowed to a net loss of $17.9M (EPS -$0.14) versus prior-year net income driven by settlement gains. Atera order demand is already above the 2026 shipment target of 40 units, but a planned Q3 sequential step-down (modest, “couple million” magnitude) reflects customers moderating existing spatial purchases ahead of Atera and manufacturing ramp constraints.

Analysis

The important signal is not the top-line guide raise; it is that TXG is in the awkward phase where a product transition suppresses near-term reported revenue while simultaneously expanding the addressable market. That usually creates a better setup for the next 2-4 quarters than the current quarter, because the mix shift from legacy instruments to a higher-value platform tends to re-rate the installed base only after utilization and consumables follow. The market is likely underestimating how much of the future value is in consumable pull-through and service attach rather than the first instrument shipment wave.

The second-order effect is competitive whiplash inside the spatial category: every customer waiting for the new platform slows purchases of the older one, which hurts short-cycle instrument revenue but can raise switching costs and standardize workflows around TXG's ecosystem. If Atera is adopted by core labs and service providers first, the company may actually centralize usage rather than broaden instrument count, which is bearish for unit placements but bullish for recurring consumables intensity over 6-18 months. That makes the near-term optics noisy and the medium-term revenue quality better than headline shipment counts suggest.

Risks are mostly timing risks. The key falsifier over the next 1-3 months is another delay in ramping Atera shipments or evidence that the transition is cannibalizing consumables more than expected. Over 6-12 months, the bigger risk is that academic funding remains trapped in approvals and order flow never converts into actual purchasing, leaving the platform narrative ahead of cash budgets. If Q4 shipments slip or consumables fail to inflect after launch, the stock likely de-rates back to a low-growth tools multiple.

Key Decisions for Investors

• Buy TXG on post-earnings weakness if the stock sells off on the Q3 revenue step-down; use a 3-6 month horizon and size for transition risk rather than immediate fundamental upside.
• For more defined risk, buy TXG 6-12 month call spreads instead of outright equity to express the 2027 consumables/attach-rate thesis while limiting damage if Atera shipments slip.
• Add a watch item on Q4 Atera shipment cadence and consumables attach; if shipment timing moves right again, reduce exposure immediately because the bull case depends on revenue recognition, not just bookings.
• If available in your book, consider a paired long TXG / short a broad life-science tools basket to isolate the Atera launch optionality from general research-funding beta.